Cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in the low endemic setting of Namibia: an analysis alongside a 2×2 factorial design cluster randomised controlled trial

Henry Ntuku, Cara Smith-Gueye, Valerie Scott, Joseph Njau, Brooke Whittemore, Brittany Zelman, Munyaradzi Tambo, Lisa M Prach, Lindsey Wu, Leah Schrubbe, Mi-Suk Kang Dufour, Agnes Mwilima, Petrina Uusiku, Hugh Sturrock, Adam Bennett, Jennifer Smith, Immo Kleinschmidt, Davis Mumbengegwi, Roly Gosling, Michelle Hsiang, Henry Ntuku, Cara Smith-Gueye, Valerie Scott, Joseph Njau, Brooke Whittemore, Brittany Zelman, Munyaradzi Tambo, Lisa M Prach, Lindsey Wu, Leah Schrubbe, Mi-Suk Kang Dufour, Agnes Mwilima, Petrina Uusiku, Hugh Sturrock, Adam Bennett, Jennifer Smith, Immo Kleinschmidt, Davis Mumbengegwi, Roly Gosling, Michelle Hsiang

Abstract

Objectives: To estimate the cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in a low endemic setting.

Setting: The study was part of a 2×2 factorial design cluster randomised controlled trial within the catchment area of 11 primary health facilities in Zambezi, Namibia.

Participants: Cost and outcome data were collected from the trial, which included 8948 community members that received interventions due to their residence within 500 m of malaria index cases.

Outcome measures: The primary outcome was incremental cost effectiveness ratio (ICER) per in incident case averted. ICER per prevalent case and per disability-adjusted life years (DALY) averted were secondary outcomes, as were per unit interventions costs and personnel time. Outcomes were compared as: (1) rfMDA versus RACD, (2) RAVC versus no RAVC and (3) rfMDA+RAVC versus RACD only.

Results: rfMDA cost 1.1× more than RACD, and RAVC cost 1.7× more than no RAVC. Relative to RACD only, the cost of rfMDA+RAVC was double ($3082 vs $1553 per event). The ICERs for rfMDA versus RACD, RAVC versus no RAVC and rfMDA+RAVC versus RACD only were $114, $1472 and $842, per incident case averted, respectively. Using prevalent infections and DALYs as outcomes, trends were similar. The median personnel time to implement rfMDA was 20% lower than for RACD (30 vs 38 min per person). The median personnel time for RAVC was 34 min per structure sprayed.

Conclusion: Implemented alone or in combination, rfMDA and RAVC were cost effective in reducing malaria incidence and prevalence despite higher implementation costs in the intervention compared with control arms. Compared with RACD, rfMDA was time saving. Cost and time requirements for the combined intervention could be decreased by implementing rfMDA and RAVC simultaneously by a single team.

Trial registration number: NCT02610400; Post-results.

Keywords: EPIDEMIOLOGY; HEALTH ECONOMICS; Health policy; Public health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Cost category breakdown for RACD, rfMDA and RAVC. RACD, reactive case detection; RAVC, reactive focal vector control; rfMDA, reactive focal mass drug administration.
Figure 2
Figure 2
Start-up and recurrent costs by comparison groups for cost per event (A), cost per person (B) and cost per PAR (C). PAR, population at risk; RACD, reactive case detection; RAVC, reactive focal vector control; rfMDA, reactive focal mass drug administration.
Figure 3
Figure 3
ICER of RACD vs rfMDA, no RAVC vs RAVC and RACD only vs rfMDA+RAVC per incident case averted, prevalent infection averted and DALY averted. DALY, disability-adjusted life years; ICER, incremental cost effectiveness ratio; RACD, reactive case detection; RAVC, reactive focal vector control; rfMDA, reactive focal mass drug administration.
Figure 4
Figure 4
Tornado diagram of change in the ICER per incident case averted for rfMDA vs RACD (A), RAVC vs no RAVC (B) and rfMDA+RAVC vs RACD only (C). The values in brackets are the range over which the parameter was varied. The vertical line is the baseline value of the ICER per incident case averted. The blue bars show the direction and magnitude of change in the ICER, when the input variable is set to its lower value and the red bars show the direction and magnitude of change when the input variable is set to its higher value. Marginal changes in the ICER are not visible on the graph. CHW, community health worker; DALY, disability-adjusted life years; ICER, incremental cost effectiveness ratio; RACD, reactive case detection; RAVC, reactive focal vector control; rfMDA, reactive focal mass drug administration.

References

    1. Feachem RGA, Phillips AA, Hwang J, et al. . Shrinking the malaria map: progress and prospects. Lancet 2010;376:1566–78. 10.1016/S0140-6736(10)61270-6
    1. WHO . World malaria report 2019, 2019.
    1. Okell LC, Ghani AC, Lyons E, et al. . Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis 2009;200:1509–17. 10.1086/644781
    1. Sturrock HJW, Hsiang MS, Cohen JM, et al. . Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med 2013;10:e1001467. 10.1371/journal.pmed.1001467
    1. Björkman A, Cook J, Sturrock H, et al. . Spatial distribution of falciparum malaria infections in Zanzibar: implications for focal drug administration strategies targeting asymptomatic parasite carriers. Clin Infect Dis 2017;64:1236–43. 10.1093/cid/cix136
    1. Bousema T, Okell L, Felger I, et al. . Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat Rev Microbiol 2014;12:833–40. 10.1038/nrmicro3364
    1. Moonen B, Cohen JM, Tatem AJ, et al. . A framework for assessing the feasibility of malaria elimination. Malar J 2010;9:322. 10.1186/1475-2875-9-322
    1. Cotter C, Sturrock HJW, Hsiang MS, et al. . The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013;382:900–11. 10.1016/S0140-6736(13)60310-4
    1. Stresman GH, Baidjoe AY, Stevenson J, et al. . Focal screening to identify the Subpatent parasite reservoir in an area of low and heterogeneous transmission in the Kenya highlands. J Infect Dis 2015;212:1768–77. 10.1093/infdis/jiv302
    1. Cook J, Xu W, Msellem M, et al. . Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis 2015;211:1476–83. 10.1093/infdis/jiu655
    1. WHO . Evidence review group report on mass drug administration. mass screening and treatment and focal screening and treatment for malaria 2015.
    1. Smith JL, Auala J, Tambo M, et al. . Spatial clustering of patent and sub-patent malaria infections in northern Namibia: implications for surveillance and response strategies for elimination. PLoS One 2017;12:e0180845. 10.1371/journal.pone.0180845
    1. Hsiang MS, Ntuku H, Roberts KW, et al. . Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet 2020;395:1361–73. 10.1016/S0140-6736(20)30470-0
    1. Zelman BW, Baral R, Zarlinda I. Costs and cost - effectiveness of malaria reactive case detection using loop - mediated isothermal amplification compared to microscopy in the low transmission setting of Aceh Province, Indonesia. Malar J 2018:1–12.
    1. Larson BA, Ngoma T, Silumbe K, et al. . A framework for evaluating the costs of malaria elimination interventions: an application to reactive case detection in Southern Province of Zambia, 2014. Malar J 2016;15:1–15. 10.1186/s12936-016-1457-5
    1. Yukich JO, Scott C, Silumbe K, et al. . Cost-Effectiveness of focal mass drug administration and mass drug administration with Dihydroartemisinin-Piperaquine for malaria prevention in southern Province, Zambia: results of a Community-Randomized controlled trial. Am J Trop Med Hyg 2020;103:46–53. 10.4269/ajtmh.19-0661
    1. Kaneko A, Taleo G, Kalkoa M, et al. . Malaria eradication on islands. The Lancet 2000;356:1560–4. 10.1016/S0140-6736(00)03127-5
    1. Bath D, Cook J, Govere J, et al. . Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa. Lancet 2021;397:816–27. 10.1016/S0140-6736(21)00251-8
    1. Ministry of Health and Social Services . National policy on malaria. Namibia, 2014.
    1. Medzihradsky OF, Kleinschmidt I, Mumbengegwi D, et al. . Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia. BMJ Open 2018;8:e019294. 10.1136/bmjopen-2017-019294
    1. World Health Organization . Indoor residual spraying: an operational manual for indoor residual spraying (IRS) for malaria transmission control and elimination.
    1. Drummond M, Sculper M, Torrnace G. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2005.
    1. OANDA . Currency converter. Available: [Accessed 9 Oct 2019].
    1. Walker D, Kumaranayake L. Allowing for differential timing in cost analyses: discounting and annualization. Health Policy Plan 2002;17:112–8. 10.1093/heapol/17.1.112
    1. Lopetegui M, Yen P-Y, Lai A, et al. . Time motion studies in healthcare: what are we talking about? J Biomed Inform 2014;49:292–9. 10.1016/j.jbi.2014.02.017
    1. Murray CJL, Vos T, Lozano R, et al. . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2197–223. 10.1016/S0140-6736(12)61689-4
    1. WHO . Global health Observatory data. Available: [Accessed 20 May 2015].
    1. Gunda R, Chimbari MJ, Mukaratirwa S. Assessment of burden of malaria in Gwanda district, Zimbabwe, using the disability adjusted life years. Int J Environ Res Public Health 2016;13:244. 10.3390/ijerph13020244
    1. World Bank . International comparison program database, 2017. Available:
    1. WHO . Cost effectiveness and strategic planning (WHO-CHOICE). Available:
    1. Sabot O, Cohen JM, Hsiang MS, et al. . Costs and financial feasibility of malaria elimination. Lancet 2010;376:1604–15. 10.1016/S0140-6736(10)61355-4
    1. Shretta R, Avanceña ALV, Hatefi A. The economics of malaria control and elimination: a systematic review. Malar J 2016;15:593. 10.1186/s12936-016-1635-5
    1. White MT, Conteh L, Cibulskis R, et al. . Costs and cost-effectiveness of malaria control interventions--a systematic review. Malar J 2011;10:337. 10.1186/1475-2875-10-337
    1. Zelman BW, Baral R, Zarlinda I, et al. . Costs and cost-effectiveness of malaria reactive case detection using loop-mediated isothermal amplification compared to microscopy in the low transmission setting of Aceh Province, Indonesia. Malar J 2018;17:1–12. 10.1186/s12936-018-2361-y
    1. Silumbe K, Yukich JO, Hamainza B, et al. . Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in southern Province, Zambia. Malar J 2015;14:1–13. 10.1186/s12936-015-0722-3
    1. Drake TL, Okello G, Njagi K, et al. . Cost analysis of school-based intermittent screening and treatment of malaria in Kenya. Malar J 2011;10:273. 10.1186/1475-2875-10-273
    1. Vaughan K, Kok MC, Witter S, et al. . Costs and cost-effectiveness of community health workers: evidence from a literature review. Hum Resour Health 2015;13:71. 10.1186/s12960-015-0070-y
    1. Liverani M, Nguon C, Sok R, et al. . Improving access to health care amongst vulnerable populations: a qualitative study of village malaria workers in Kampot, Cambodia. BMC Health Serv Res 2017;17:335. 10.1186/s12913-017-2282-4
    1. Eisele TP, Bennett A, Silumbe K, et al. . Impact of four rounds of mass drug administration with Dihydroartemisinin-Piperaquine implemented in southern Province, Zambia. Am J Trop Med Hyg 2020;103:7–18. 10.4269/ajtmh.19-0659
    1. Okebe J, Ribera JM, Balen J. Reactive community-based self- administered treatment against residual malaria transmission : study protocol for a randomized controlled trial. Trials 2018:1–8.
    1. Galactionova K, Velarde M, Silumbe K, et al. . Costing malaria interventions from pilots to elimination programmes. Malar J 2020;19:332. 10.1186/s12936-020-03405-3
    1. Antillon M, Huang C-I, Rock KS, et al. . Economic evaluation of disease elimination: an extension to the net-benefit framework and application to human African trypanosomiasis. Proc Natl Acad Sci U S A 2021;118. 10.1073/pnas.2026797118. [Epub ahead of print: 14 12 2021].

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅